Skip to main content
Journal cover image

Vasopressin receptor antagonists.

Publication ,  Journal Article
Greenberg, A; Verbalis, JG
Published in: Kidney Int
June 2006

The first non-peptide vasopressin receptor antagonist (VRA) was recently approved by the United States Food and Drug Administration, and several others are now in late stages of clinical development. Phase 3 trials indicate that these agents predictably reduce urine osmolality, increase electrolyte-free water excretion, and raise serum sodium concentration. They are likely to become a mainstay of treatment of euvolemic and hypervolemic hyponatremia. Although tachyphylaxis to the hydro-osmotic effect of these agents does not appear to occur, their use is accompanied by an increase in thirst, and they do not always eliminate altogether the need for water restriction during treatment of hyponatremia. Experience with use of these agents for treatment of acute, severe, life-threatening hyponatremia as well as chronic hyponatremia is limited. Further studies are needed to determine how they are best used in these situations, but the risk of overly rapid correction of hyponatremia seems low. Results of long-term trials to determine the ability of VRAs to reduce morbidity or mortality in congestive heart failure or to slow the progression of polycystic kidney disease are awaited with great interest.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Kidney Int

DOI

ISSN

0085-2538

Publication Date

June 2006

Volume

69

Issue

12

Start / End Page

2124 / 2130

Location

United States

Related Subject Headings

  • Vasopressins
  • Urology & Nephrology
  • United States Food and Drug Administration
  • United States
  • Tolvaptan
  • Sodium
  • Receptors, Vasopressin
  • Pyrroles
  • Polycystic Kidney Diseases
  • Osmolar Concentration
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Greenberg, A., & Verbalis, J. G. (2006). Vasopressin receptor antagonists. Kidney Int, 69(12), 2124–2130. https://doi.org/10.1038/sj.ki.5000432
Greenberg, A., and J. G. Verbalis. “Vasopressin receptor antagonists.Kidney Int 69, no. 12 (June 2006): 2124–30. https://doi.org/10.1038/sj.ki.5000432.
Greenberg A, Verbalis JG. Vasopressin receptor antagonists. Kidney Int. 2006 Jun;69(12):2124–30.
Greenberg, A., and J. G. Verbalis. “Vasopressin receptor antagonists.Kidney Int, vol. 69, no. 12, June 2006, pp. 2124–30. Pubmed, doi:10.1038/sj.ki.5000432.
Greenberg A, Verbalis JG. Vasopressin receptor antagonists. Kidney Int. 2006 Jun;69(12):2124–2130.
Journal cover image

Published In

Kidney Int

DOI

ISSN

0085-2538

Publication Date

June 2006

Volume

69

Issue

12

Start / End Page

2124 / 2130

Location

United States

Related Subject Headings

  • Vasopressins
  • Urology & Nephrology
  • United States Food and Drug Administration
  • United States
  • Tolvaptan
  • Sodium
  • Receptors, Vasopressin
  • Pyrroles
  • Polycystic Kidney Diseases
  • Osmolar Concentration